Home
Mail
News
Sports
Finance
Celebrity
Style
Movies
Weather
Mobile
Yahoo
Mail
News
Taxes
Watchlists
My Portfolio
Real Estate
My Screeners
Tech
Market Data
Industry News
Currency Converter
Canada markets closed
S&P/TSX
22,167.03
+59.95
(+0.27%)
S&P 500
5,254.35
+5.86
(+0.11%)
DOW
39,807.37
+47.29
(+0.12%)
CAD/USD
0.7389
+0.0016
(+0.22%)
CRUDE OIL
83.11
-0.06
(-0.07%)
Bitcoin CAD
95,847.59
+2,250.84
(+2.40%)
Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.9200
-0.0200
(-0.40%)
At close: 04:00PM EDT
5.1300
+0.21
(+4.27%)
After hours:
05:02PM EDT
Summary
Chart
Conversations
Statistics
Historical Data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly
Income Statement
All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Total Revenue
234,040
234,040
132,565
77,798
15,325
Cost of Revenue
74,363
74,363
51,667
23,410
4,769
Gross Profit
159,677
159,677
80,898
54,388
10,556
Operating Expenses
Research Development
79,410
79,410
101,286
116,255
125,795
Selling General and Administrative
292,238
292,238
219,696
198,821
151,846
Total Operating Expenses
382,012
382,012
353,067
329,064
283,718
Operating Income or Loss
-222,335
-222,335
-272,169
-274,676
-273,162
Interest Expense
19,356
19,356
16,474
6,273
15,148
Total Other Income/Expenses Net
-95,280
-95,280
-71,970
-698
-721
Income Before Tax
-323,686
-323,686
-355,722
-281,310
-284,709
Income Tax Expense
300
300
700
0
-2,620
Income from Continuing Operations
-323,986
-323,986
-356,422
-281,310
-282,089
Net Income
-323,986
-323,986
-356,422
-281,310
-282,089
Net Income available to common shareholders
-323,986
-323,986
-356,422
-281,310
-282,089
Basic EPS
-5.10
-3.83
-4.90
-4.17
-4.86
Diluted EPS
-5.10
-3.83
-4.90
-4.17
-4.86
Basic Average Shares
82,914
84,599
72,713
67,508
58,009
Diluted Average Shares
82,914
84,599
72,713
67,508
58,009
Data Disclaimer
Help
Suggestions
Terms (Updated)
and
Privacy Policy
Your Privacy Choices
About Our Ads
© 2024 Yahoo. All rights reserved.